Severe alopecia areata
Clinical trials for Severe alopecia areata explained in plain language.
Never miss a new study
Get alerted when new Severe alopecia areata trials appear
Sign up with your email to follow new studies for Severe alopecia areata, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a JAK inhibitor bring back hair in kids with severe alopecia?
Disease control Recruiting nowThis trial tests whether upadacitinib, an oral medication that calms the immune system, can help children with severe alopecia areata—a condition where the immune system attacks hair follicles, causing significant hair loss. Children aged 6 to 17 with at least 50% scalp hair loss…
Matched conditions: SEVERE ALOPECIA AREATA
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill could regrow hair in severe alopecia – trial begins
Disease control Recruiting nowThis study tests a drug called deuruxolitinib in Japanese adults aged 18-65 with severe alopecia areata, an autoimmune condition causing significant scalp hair loss. Participants must have at least 50% hair loss. The trial measures how well the drug regrows hair and how satisfied…
Matched conditions: SEVERE ALOPECIA AREATA
Phase 3 • Sponsor: Sun Pharma Japan Limited • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug litfulo tracked in 3,000 patients for hair loss treatment
Disease control Recruiting nowThis study is monitoring the safety and effectiveness of Litfulo (Ritlecitinib) in 3,000 people with severe alopecia areata, a condition causing patchy hair loss. Participants take the drug as prescribed in real-world clinics across Korea. Researchers will track side effects and …
Matched conditions: SEVERE ALOPECIA AREATA
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Hair loss drug ritlecitinib tested for Long-Term safety in teens
Disease control Recruiting nowThis study looks at the long-term safety and effects of the drug ritlecitinib for severe alopecia areata, a condition causing significant hair loss. It involves 140 teens who previously completed Pfizer studies on this drug. Participants take a daily capsule for up to 3 years, wi…
Matched conditions: SEVERE ALOPECIA AREATA
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New antibody drug aims to halt skin and hair loss
Disease control Recruiting nowThis early-stage trial tests a new drug called IBI3013, which blocks a protein (IL-15) involved in immune attacks. It includes 160 people: healthy volunteers first, then people with active vitiligo or severe alopecia areata. The main goal is to check safety and how the drug moves…
Matched conditions: SEVERE ALOPECIA AREATA
Phase 1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC